intrommune_icon_500x500.png
Intrommune Participates in the Forsyth dentech 2021 Conference
September 22, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
September 21, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
September 08, 2021 10:02 ET | Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
intrommune_icon_500x500.png
Intrommune Therapeutics Launches #PeanutAllergyStrong
August 24, 2021 12:25 ET | Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
August 11, 2021 13:37 ET | Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Appoints Sergi Trilla, MD, MBA to its Scientific and Business Advisory Boards
July 28, 2021 14:10 ET | Intrommune Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Presents at Next Generation Food Allergy Drug Summit
July 22, 2021 16:57 ET | Intrommune Therapeutics
NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics to Present at BIO Digital 2021
June 17, 2021 09:11 ET | Intrommune Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
intrommune_icon_500x500.png
Intrommune Therapeutics Names Chief Operating Officer
March 25, 2021 09:10 ET | Intrommune Therapeutics
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
intrommune_icon_500x500.png
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
March 12, 2021 09:30 ET | Intrommune Therapeutics
NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- The clinical and scientific team of Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing patient-friendly treatments...